No connection

Search Results

ACHC vs STOK

ACHC
Acadia Healthcare Company, Inc.
BEARISH
Price
$23.52
Market Cap
$2.17B
Sector
Healthcare
AI Confidence
85%
STOK
Stoke Therapeutics, Inc.
BEARISH
Price
$37.27
Market Cap
$2.2B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACHC
--
STOK
--
Forward P/E
ACHC
14.03
STOK
-11.73
P/B Ratio
ACHC
1.09
STOK
6.23
P/S Ratio
ACHC
0.65
STOK
11.95
EV/EBITDA
ACHC
8.46
STOK
-102.23

Profitability

Gross Margin
ACHC
41.48%
STOK
100.0%
Operating Margin
ACHC
5.8%
STOK
-4382.24%
Profit Margin
ACHC
-33.29%
STOK
-3.73%
ROE
ACHC
-40.96%
STOK
-2.37%
ROA
ACHC
4.22%
STOK
-3.73%

Growth

Revenue Growth
ACHC
6.1%
STOK
-93.8%
Earnings Growth
ACHC
--
STOK
--

Financial Health

Debt/Equity
ACHC
1.24
STOK
0.01
Current Ratio
ACHC
1.55
STOK
5.28
Quick Ratio
ACHC
1.29
STOK
5.05

Dividends

Dividend Yield
ACHC
--
STOK
--
Payout Ratio
ACHC
0.0%
STOK
0.0%

AI Verdict

ACHC BEARISH

ACHC's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining earnings, and high leverage. The absence of an Altman Z-Score and negative ROE (-40.96%) raise significant bankruptcy risk concerns. Despite a modest forward P/E of 14.03 and strong recent earnings surprises, the company's negative profit margin (-33.29%) and massive year-over-year EPS decline (-89.1%) undermine its fundamentals. The stock's 5-year price drop of 61.4% and lack of dividend support further signal investor skepticism. Analysts recommend 'buy' but with limited conviction, as the underlying financial health remains fragile.

Strengths
Recent quarterly earnings have consistently beaten estimates (3/4 in last 4 quarters)
Strong average earnings surprise of 206.53% over the last 4 quarters
Positive revenue growth of 6.10% YoY, outpacing many peers
Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and high distress risk
Negative profit margin (-33.29%) and ROE (-40.96%) reflect deep profitability issues
Debt/Equity ratio of 1.24 is elevated for a healthcare facility operator, especially with negative earnings
STOK BEARISH

STOK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. Despite a massive 1-year price surge of 384.7%, the company is facing a catastrophic revenue decline of 93.8% and significant operating losses. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $3.75M in shares. The current valuation is speculative, unsupported by earnings or growth metrics.

Strengths
Very strong liquidity with a Current Ratio of 5.28
Negligible debt levels (Debt/Equity of 0.01)
Strong analyst support with a 'Strong Buy' consensus
Risks
Severe revenue collapse (-93.8% YoY)
Extremely weak Piotroski F-Score (2/9)
Deeply negative operating margins (-4382.24%)

Compare Another Pair

ACHC vs STOK: Head-to-Head Comparison

This page compares Acadia Healthcare Company, Inc. (ACHC) and Stoke Therapeutics, Inc. (STOK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile